China Price To Sales Ratio from 2010 to 2025
| CPHI Stock | USD 0.22 0.02 8.33% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 0.34 | Current Value 0.32 | Quarterly Volatility 8.4 K |
Check China Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among China Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.3 M, Interest Expense of 350.4 K or Selling General Administrative of 1.3 M, as well as many indicators such as Price To Sales Ratio of 0.32, Dividend Yield of 5.0E-4 or PTB Ratio of 0.26. China financial statements analysis is a perfect complement when working with China Pharma Valuation or Volatility modules.
China | Price To Sales Ratio |
Latest China Pharma's Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of China Pharma Holdings over the last few years. Price to Sales Ratio is figured by comparing China Pharma Holdings stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on China Pharma sales, a figure that is much harder to manipulate than other China Pharma Holdings multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. China Pharma's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in China Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.67 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
China Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 2,099 | |
| Geometric Mean | 3.84 | |
| Coefficient Of Variation | 399.34 | |
| Mean Deviation | 3,930 | |
| Median | 3.11 | |
| Standard Deviation | 8,383 | |
| Sample Variance | 70.3M | |
| Range | 33.5K | |
| R-Value | (0.42) | |
| Mean Square Error | 62M | |
| R-Squared | 0.18 | |
| Significance | 0.11 | |
| Slope | (739.66) | |
| Total Sum of Squares | 1.1B |
China Price To Sales Ratio History
About China Pharma Financial Statements
Investors use fundamental indicators, such as China Pharma's Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although China Pharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 0.34 | 0.32 |
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out the analysis of China Pharma Correlation against competitors. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share | Quarterly Revenue Growth (0.16) | Return On Assets | Return On Equity |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.